Glasgow Prognostic Score as a Marker of Mortality after TAVI

Detalhes bibliográficos
Autor(a) principal: Abacioglu,Ozge Ozcan
Data de Publicação: 2021
Outros Autores: Koyunsever,Nermin Yildiz, Kilic,Salih, Yildirim,Arafat, Kurt,Ibrahim Halil
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Cardiovascular Surgery (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382021000600796
Resumo: Abstract Introduction: The Glasgow prognostic score (GPS) reflects host systemic inflammatory response and has been reported to be significant as a prognostic indicator in cancer-bearing patients. The aim of this study was to evaluate the predictive value of GPS in outcomes of patients with severe aortic stenosis who were treated with transcatheter aortic valve implantation (TAVI). Methods: The study population consisted of 79 patients who underwent TAVI due to severe aortic stenosis between January 2018 and March 2019 in our clinic. Echocardiographic and laboratory data were recorded before the procedure and GPS was scored as 0, 1, or 2, based on serum albumin and C-reactive protein levels. European System for Cardiac Operative Risk Evaluation II scoring system was used for risk stratification. The primary endpoints of the study were postoperative in-hospital mortality, hospitalization due to cardiac causes, or mortality within a year. Results: The 79 patients were classified into two groups according to outcomes. Fifteen patients (19%) reached the primary endpoints at one year of follow-up. Compared to the patients who did not reach the endpoints, these 15 patients were not different in terms of age, preoperative mean gradient, and ejection fraction (P>0.05 for all). GPS was the only laboratory parameter with statistically significant difference between the groups (P=0.008) and multivariate analysis showed that GPS was independent predictor of primary endpoints (P=0.012, odds ratio 4.51, 95% confidence interval 1.39-14.60). Conclusion: GPS is an easy, noninvasive laboratory test which may be used as a predictive biomarker for outcomes in patients undergoing TAVI.
id SBCCV-1_93f4e4ae78c928f7748902dd3dd6b655
oai_identifier_str oai:scielo:S0102-76382021000600796
network_acronym_str SBCCV-1
network_name_str Brazilian Journal of Cardiovascular Surgery (Online)
repository_id_str
spelling Glasgow Prognostic Score as a Marker of Mortality after TAVITranscatheter Aortic Valve ReplacementAortic Valve StenosisC-Reactive ProteinHospital MortalityPrognosisSerum AlbuminAbstract Introduction: The Glasgow prognostic score (GPS) reflects host systemic inflammatory response and has been reported to be significant as a prognostic indicator in cancer-bearing patients. The aim of this study was to evaluate the predictive value of GPS in outcomes of patients with severe aortic stenosis who were treated with transcatheter aortic valve implantation (TAVI). Methods: The study population consisted of 79 patients who underwent TAVI due to severe aortic stenosis between January 2018 and March 2019 in our clinic. Echocardiographic and laboratory data were recorded before the procedure and GPS was scored as 0, 1, or 2, based on serum albumin and C-reactive protein levels. European System for Cardiac Operative Risk Evaluation II scoring system was used for risk stratification. The primary endpoints of the study were postoperative in-hospital mortality, hospitalization due to cardiac causes, or mortality within a year. Results: The 79 patients were classified into two groups according to outcomes. Fifteen patients (19%) reached the primary endpoints at one year of follow-up. Compared to the patients who did not reach the endpoints, these 15 patients were not different in terms of age, preoperative mean gradient, and ejection fraction (P>0.05 for all). GPS was the only laboratory parameter with statistically significant difference between the groups (P=0.008) and multivariate analysis showed that GPS was independent predictor of primary endpoints (P=0.012, odds ratio 4.51, 95% confidence interval 1.39-14.60). Conclusion: GPS is an easy, noninvasive laboratory test which may be used as a predictive biomarker for outcomes in patients undergoing TAVI.Sociedade Brasileira de Cirurgia Cardiovascular2021-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382021000600796Brazilian Journal of Cardiovascular Surgery v.36 n.6 2021reponame:Brazilian Journal of Cardiovascular Surgery (Online)instname:Sociedade Brasileira de Cirurgia Cardiovascular (SBCCV)instacron:SBCCV10.21470/1678-9741-2020-0269info:eu-repo/semantics/openAccessAbacioglu,Ozge OzcanKoyunsever,Nermin YildizKilic,SalihYildirim,ArafatKurt,Ibrahim Halileng2021-12-02T00:00:00Zoai:scielo:S0102-76382021000600796Revistahttp://www.rbccv.org.br/https://old.scielo.br/oai/scielo-oai.php||rosangela.monteiro@incor.usp.br|| domingo@braile.com.br|| brandau@braile.com.br1678-97410102-7638opendoar:2021-12-02T00:00Brazilian Journal of Cardiovascular Surgery (Online) - Sociedade Brasileira de Cirurgia Cardiovascular (SBCCV)false
dc.title.none.fl_str_mv Glasgow Prognostic Score as a Marker of Mortality after TAVI
title Glasgow Prognostic Score as a Marker of Mortality after TAVI
spellingShingle Glasgow Prognostic Score as a Marker of Mortality after TAVI
Abacioglu,Ozge Ozcan
Transcatheter Aortic Valve Replacement
Aortic Valve Stenosis
C-Reactive Protein
Hospital Mortality
Prognosis
Serum Albumin
title_short Glasgow Prognostic Score as a Marker of Mortality after TAVI
title_full Glasgow Prognostic Score as a Marker of Mortality after TAVI
title_fullStr Glasgow Prognostic Score as a Marker of Mortality after TAVI
title_full_unstemmed Glasgow Prognostic Score as a Marker of Mortality after TAVI
title_sort Glasgow Prognostic Score as a Marker of Mortality after TAVI
author Abacioglu,Ozge Ozcan
author_facet Abacioglu,Ozge Ozcan
Koyunsever,Nermin Yildiz
Kilic,Salih
Yildirim,Arafat
Kurt,Ibrahim Halil
author_role author
author2 Koyunsever,Nermin Yildiz
Kilic,Salih
Yildirim,Arafat
Kurt,Ibrahim Halil
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Abacioglu,Ozge Ozcan
Koyunsever,Nermin Yildiz
Kilic,Salih
Yildirim,Arafat
Kurt,Ibrahim Halil
dc.subject.por.fl_str_mv Transcatheter Aortic Valve Replacement
Aortic Valve Stenosis
C-Reactive Protein
Hospital Mortality
Prognosis
Serum Albumin
topic Transcatheter Aortic Valve Replacement
Aortic Valve Stenosis
C-Reactive Protein
Hospital Mortality
Prognosis
Serum Albumin
description Abstract Introduction: The Glasgow prognostic score (GPS) reflects host systemic inflammatory response and has been reported to be significant as a prognostic indicator in cancer-bearing patients. The aim of this study was to evaluate the predictive value of GPS in outcomes of patients with severe aortic stenosis who were treated with transcatheter aortic valve implantation (TAVI). Methods: The study population consisted of 79 patients who underwent TAVI due to severe aortic stenosis between January 2018 and March 2019 in our clinic. Echocardiographic and laboratory data were recorded before the procedure and GPS was scored as 0, 1, or 2, based on serum albumin and C-reactive protein levels. European System for Cardiac Operative Risk Evaluation II scoring system was used for risk stratification. The primary endpoints of the study were postoperative in-hospital mortality, hospitalization due to cardiac causes, or mortality within a year. Results: The 79 patients were classified into two groups according to outcomes. Fifteen patients (19%) reached the primary endpoints at one year of follow-up. Compared to the patients who did not reach the endpoints, these 15 patients were not different in terms of age, preoperative mean gradient, and ejection fraction (P>0.05 for all). GPS was the only laboratory parameter with statistically significant difference between the groups (P=0.008) and multivariate analysis showed that GPS was independent predictor of primary endpoints (P=0.012, odds ratio 4.51, 95% confidence interval 1.39-14.60). Conclusion: GPS is an easy, noninvasive laboratory test which may be used as a predictive biomarker for outcomes in patients undergoing TAVI.
publishDate 2021
dc.date.none.fl_str_mv 2021-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382021000600796
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382021000600796
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.21470/1678-9741-2020-0269
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Cirurgia Cardiovascular
publisher.none.fl_str_mv Sociedade Brasileira de Cirurgia Cardiovascular
dc.source.none.fl_str_mv Brazilian Journal of Cardiovascular Surgery v.36 n.6 2021
reponame:Brazilian Journal of Cardiovascular Surgery (Online)
instname:Sociedade Brasileira de Cirurgia Cardiovascular (SBCCV)
instacron:SBCCV
instname_str Sociedade Brasileira de Cirurgia Cardiovascular (SBCCV)
instacron_str SBCCV
institution SBCCV
reponame_str Brazilian Journal of Cardiovascular Surgery (Online)
collection Brazilian Journal of Cardiovascular Surgery (Online)
repository.name.fl_str_mv Brazilian Journal of Cardiovascular Surgery (Online) - Sociedade Brasileira de Cirurgia Cardiovascular (SBCCV)
repository.mail.fl_str_mv ||rosangela.monteiro@incor.usp.br|| domingo@braile.com.br|| brandau@braile.com.br
_version_ 1752126602713497600